Display options
Cite
Seo EJ, Dawood M, Hult AK, et al. Network pharmacology of triptolide in cancer cells: implications for transcription factor binding. Invest New Drugs. 2021;39(6):1523-1537doi: 10.1007/s10637-021-01137-y.
Seo, E. J., Dawood, M., Hult, A. K., Olsson, M. L., & Efferth, T. (2021). Network pharmacology of triptolide in cancer cells: implications for transcription factor binding. Investigational new drugs, 39(6), 1523-1537. https://doi.org/10.1007/s10637-021-01137-y
Seo, Ean-Jeong, et al. "Network pharmacology of triptolide in cancer cells: implications for transcription factor binding." Investigational new drugs vol. 39,6 (2021): 1523-1537. doi: https://doi.org/10.1007/s10637-021-01137-y
Seo EJ, Dawood M, Hult AK, Olsson ML, Efferth T. Network pharmacology of triptolide in cancer cells: implications for transcription factor binding. Invest New Drugs. 2021 Dec;39(6):1523-1537. doi: 10.1007/s10637-021-01137-y. Epub 2021 Jul 02. PMID: 34213719; PMCID: PMC8541937.
Copy Download .nbib Format: NLM
Share it on

Invest New Drugs. 2021 Dec;39(6):1523-1537. doi: 10.1007/s10637-021-01137-y. Epub 2021 Jul 02.

Network pharmacology of triptolide in cancer cells: implications for transcription factor binding.

Investigational new drugs

Ean-Jeong Seo, Mona Dawood, Annika K Hult, Martin L Olsson, Thomas Efferth

Affiliations

  1. Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, 55128, Mainz, Germany.
  2. Department of Molecular Biology, Faculty of Medical Laboratory Sciences, Al-Neelain University, Khartoum, Sudan.
  3. Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, 221 84, Lund, Sweden.
  4. Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, 55128, Mainz, Germany. [email protected].

PMID: 34213719 PMCID: PMC8541937 DOI: 10.1007/s10637-021-01137-y

Abstract

Background Triptolide is an active natural product, which inhibits cell proliferation, induces cell apoptosis, suppresses tumor metastasis and improves the effect of other therapeutic treatments in several cancer cell lines by affecting multiple molecules and signaling pathways, such as caspases, heat-shock proteins, DNA damage and NF-ĸB. Purpose We investigated the effect of triptolide towards NF-ĸB and GATA1. Methods We used cell viability assay, compare and cluster analyses of microarray-based mRNA transcriptome-wide expression data, gene promoter binding motif analysis, molecular docking, Ingenuity pathway analysis, NF-ĸB reporter cell assay, and electrophoretic mobility shift assay (EMSA) of GATA1. Results Triptolide inhibited the growth of drug-sensitive (CCRF-CEM, U87.MG) and drug-resistant cell lines (CEM/ADR5000, U87.MGΔEGFR). Hierarchical cluster analysis showed six major clusters in dendrogram. The sensitive and resistant cell lines were statistically significant (p = 0.65 × 10

© 2021. The Author(s).

Keywords: Microarrays; Natural products; Network pharmacology; Phytochemicals; Precision medicine

References

  1. Int J Oncol. 2016 Apr;48(4):1519-30 - PubMed
  2. Genome Biol. 2011 Aug 22;12(8):R83 - PubMed
  3. PLoS One. 2015 Jul 24;10(7):e0133003 - PubMed
  4. Front Pharmacol. 2018 Feb 27;9:143 - PubMed
  5. Springerplus. 2016 Sep 27;5(1):1666 - PubMed
  6. Oncotarget. 2015 Apr 10;6(10):8019-35 - PubMed
  7. J Clin Invest. 2007 Aug;117(8):2051-8 - PubMed
  8. Hematology. 2019 Dec;24(1):487-491 - PubMed
  9. Invest New Drugs. 2014 Aug;32(4):618-25 - PubMed
  10. Science. 1997 Jan 17;275(5298):343-9 - PubMed
  11. Nat Rev Immunol. 2002 Oct;2(10):725-34 - PubMed
  12. Blood. 2016 Sep 15;128(11):1503-15 - PubMed
  13. Phytomedicine. 2011 Aug 15;18(11):959-69 - PubMed
  14. Cancer Res. 2008 Jan 15;68(2):415-24 - PubMed
  15. Sci Transl Med. 2012 Oct 17;4(156):156ra139 - PubMed
  16. Chem Sci. 2015 Jul 15;6(7):4124-4130 - PubMed
  17. Semin Cancer Biol. 2003 Apr;13(2):107-14 - PubMed
  18. Biomed Pharmacother. 2014 Jun;68(5):527-35 - PubMed
  19. Evid Based Complement Alternat Med. 2012;2012:350239 - PubMed
  20. PLoS One. 2012;7(5):e35584 - PubMed
  21. Annu Rev Biochem. 1993;62:385-427 - PubMed
  22. Mol Cancer Ther. 2003 Jan;2(1):65-72 - PubMed
  23. Int J Oncol. 2013 Oct;43(4):1169-75 - PubMed
  24. Nat Genet. 2000 Mar;24(3):236-44 - PubMed
  25. Genes Cancer. 2010 Dec;1(12):1178-88 - PubMed
  26. Nat Rev Cancer. 2002 Oct;2(10):740-9 - PubMed
  27. J Ethnopharmacol. 2016 Dec 4;193:333-344 - PubMed
  28. Trends Pharmacol Sci. 2009 Oct;30(10):546-56 - PubMed
  29. Mol Pharmacol. 2003 Aug;64(2):382-94 - PubMed
  30. Nat Rev Cancer. 2008 Apr;8(4):279-87 - PubMed
  31. Chin J Cancer Res. 2014 Oct;26(5):622-6 - PubMed
  32. J Nutr Biochem. 2015 Jan;26(1):44-56 - PubMed
  33. Cancer Res. 1988 Feb 1;48(3):589-601 - PubMed
  34. BMC Complement Altern Med. 2016 Aug 02;16:267 - PubMed
  35. Nucleic Acids Res. 1991 May 11;19(9):2499 - PubMed
  36. Br J Clin Pharmacol. 2012 Sep;74(3):424-36 - PubMed
  37. Genes Cells. 2002 Dec;7(12):1243-54 - PubMed
  38. J Nat Prod. 2015 Apr 24;78(4):762-75 - PubMed
  39. Nat Rev Drug Discov. 2009 Jan;8(1):33-40 - PubMed
  40. J Am Chem Soc. 1972 Oct 4;94(20):7194-5 - PubMed
  41. J Cell Physiol. 2005 Oct;205(1):1-9 - PubMed
  42. Exp Cell Res. 2015 Feb 15;331(2):362-8 - PubMed
  43. Adv Cancer Res. 1963;7:235-50 - PubMed
  44. Org Biomol Chem. 2010 Jul 21;8(14):3149-56 - PubMed
  45. Eur J Biochem. 2000 Sep;267(17):5421-6 - PubMed
  46. J Natl Cancer Inst. 1997 Oct 15;89(20):1505-15 - PubMed
  47. Front Pharmacol. 2019 May 21;10:542 - PubMed
  48. Phytomedicine. 2016 Mar 15;23(3):293-306 - PubMed
  49. Eur J Med Chem. 2017 Sep 29;138:273-292 - PubMed
  50. Blood. 2018 Jul 19;132(3):334-338 - PubMed
  51. Clin Cancer Res. 2002 Aug;8(8):2666-74 - PubMed
  52. Cancer Res. 2003 Oct 15;63(20):6962-70 - PubMed
  53. Cancer Chemother Pharmacol. 2008 Mar;61(3):377-93 - PubMed
  54. Nat Chem Biol. 2011 Mar;7(3):182-8 - PubMed
  55. Mol Cancer Ther. 2016 Jul;15(7):1495-503 - PubMed

Publication Types